BFC Planning’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.01K Buy
81
+22
+37% +$1.31K ﹤0.01% 2883
2026
Q2
$3.56K Hold
59
– – ﹤0.01% 2807
2026
Q1
$3.43K Hold
59
– – ﹤0.01% 2445
2025
Q4
$2.64K Hold
59
– – ﹤0.01% 2551
2025
Q3
$2.37K Hold
59
– – ﹤0.01% 2431
2025
Q2
$1.85K Hold
59
– – ﹤0.01% 2326
2025
Q1
$1.98K Hold
59
– – ﹤0.01% 2309
2024
Q4
$2.31K Hold
59
– – ﹤0.01% 2251
2024
Q3
$2.32K Buy
+59
New +$2.38K ﹤0.01% 2248

Other funds holding XENE

BFC Planning's XENE Position: Q3 2026 in Review

BFC Planning increased its Xenon Pharmaceuticals (XENE) stake by 37% in Q3 2026, buying an estimated $1.31K and bringing the position to 81 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

BFC Planning first reported a position in XENE in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.56K in Q2 2026. 196 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • BFC Planning held 81 shares of Xenon Pharmaceuticals worth $3.01K as of Q3 2026.
  • BFC Planning bought 22 Xenon Pharmaceuticals shares in Q3 2026, an estimated $1.31K.
  • Xenon Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2883 holding.
  • BFC Planning first reported a position in Xenon Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Xenon Pharmaceuticals position peaked at $3.56K in Q2 2026.
  • 196 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.